Regentis Biomaterials (NYSE American: RGNT) has announced a significant scale-up in the manufacturing of its GelrinC hydrogel implant, a cell-free, off-the-shelf treatment designed to regenerate durable, natural-like cartilage in patients with painful knee cartilage injuries. The company reported that European regulatory approval of a new solvent-free process has increased production yield by 400%, a development that could enhance supply efficiency and support the company's commercialization plans.
The manufacturing milestone comes as Regentis continues to advance its U.S. pivotal Phase III trial, where 43 of 80 planned patients have been treated. Enrollment is expected to conclude around the end of 2026. The company is also preparing for potential European commercialization under its existing CE Mark approval, positioning GelrinC for market entry in a region where regulatory clearance is already in place.
GelrinC is designed to temporarily fill cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, and the company has reported greater pain improvement than traditional microfracture. These clinical outcomes, combined with the manufacturing scale-up, could strengthen Regentis' competitive position in the cartilage repair market.
The addressable market is substantial: approximately 470,000 cases of cartilage knee repair occur annually in the U.S., according to the company, where no off-the-shelf treatment is currently available. GelrinC aims to fill that gap with an off-the-shelf solution that avoids the need for cell harvesting or additional procedures. For a deeper look at Regentis' technology and trial progress, the full article is available at https://nnw.fm/JiVLN.
Investors and industry observers can find the latest news and updates relating to RGNT in the company’s newsroom at https://nnw.fm/RGNT. The announcement was disseminated through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For full terms and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
